Blog Detail

PorTal Access, a pioneering medical device company on a mission to improve vascular access solutions for cancer patients, has announced it has secured a $7 million Series A round. The Miami-based company reports that $6 million of the round is from U.S.-based physicians such as oncologists, interventional radiologists and vascular surgeons.

The funding will help support the company’s regulatory path ahead: the submission of a 510(k) application to the U.S. Food and Drug Administration for its Flexi-Port SLF-TANL device. This innovative device is designed to streamline vascular access for oncology patients, simplifying the process while enhancing usability and reducing associated complexities. The 510(k) submission is projected for July 2025. The company hopes to launch the device in 2026.

“Closing this funding round represents an important milestone as we work toward regulatory approval. Flexi-Port SLF-TANL is engineered with a focus on simplicity, stability, and scalability — likely to support more efficient workflows in oncology access settings. It’s a solution for both clinicians and patients and created with the most optimal patient outcome and experience in mind,” said Dr. Michael Tal, founder and CEO of PorTal Access, in a statement.

Tal, an interventional radiologist who earned his medical degree at the Hebrew University in Jerusalem, is a serial inventor/entrepreneur with over 200 patents to his name and a few other medical devices in development.  

Despite being a common aspect of cancer treatment, many patients do not receive chemotherapy ports due to delays in treatment and other barriers. With the introduction of the Flexi-Port SLF-TANL, PorTal Access aims to minimize these hurdles, potentially reducing treatment delays and procedural risks, while also lowering overall healthcare costs, the company says in its announcement of the funding. The goal: Improving the patient experience and operational efficiency across cancer care delivery.

“We are seeing significant interest from clinics and hospitals across the country, many of which are already preparing to integrate the Flexi-Port SLF-TANLinto their practice as soon as it becomes available,’ said Angela Dotson, PorTal Access’s executive VP of Business Development. “They’ve been waiting more than 30 years for an innovation like this. Today, we are one step closer to delivering this transformative solution to clinicians and their patients.”

As PorTal Access rises from stealth (no website yet) with this funding, it joins a healthy medical tech startup community and healthcare ecosystem in South Florida. Indeed, medtech companies – including medical devices, pharma, biotech and healthtech —  attracted $572.5 million across 45 deals in 2024. Medtech has been among South Florida’s top two sectors for venture funding over at least the past six years.

READ MORE IN REFRESH MIAMI:

Boca-based healthtech Dazos raises $25M Series A

Theator is bringing surgical intelligence into the operating room

Miami-based Swift Sync’s novel heart pacing catheter is making its way through the FDA process

Clinical trials underway for stem cell-derived ointment for blistering skin disorders

With $10M in tow, Kiwi takes on Latin America’s $60 billion healthcare gap

Healthtech startup Definition Health sets sights on Miami to streamline surgery care with AI